<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03039049</url>
  </required_header>
  <id_info>
    <org_study_id>02053779</org_study_id>
    <nct_id>NCT03039049</nct_id>
  </id_info>
  <brief_title>GNRH Agonist Trigger and Modified Luteal Phase Adding a Bolus of GnRHa at the Time of Implantation: a RCT</brief_title>
  <official_title>GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Mid-luteal Bolus of GnRHa: a Randomised Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Ibn Rochd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Ibn Rochd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:The aim of this project is to prospectively determine whether a single dose of
      GnRH-agonist administered at the time of implantation increases or not the reproductive
      outcome in patients undergoing in vitro fertilization ( IVF)/ intracytoplasmatic sperm
      injection(ICSI) triggered by a GnRH-agonist followed by a small bolus of human chorionic
      gonadotropin (hCG 1500 IU) the day of oocyte retrieval.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been reported in previous publications that the ovarian hyperstimulation syndrome
      (OHSS) was eliminated when GnRH agonist was used to trigger ovulation and the delivery rate
      has improved after modified luteal support especially when a small bolus of hCG is used on
      the day of oocyte retrieval. (OMEGA/HCG 1500 IU).

      However, a risk difference of 7% in delivery rates is still in favor of HCG trigger. Thus,
      further modifications in the luteal phase supplementation are required in order to optimise
      the reproductive outcome after GnRH-agonist triggering.

      Recently, many papers showed, that independently of the GnRH analogue used to prevent the
      premature LH surge, the addition of GnRH-agonist during the luteal phase seems to be
      beneficial in terms of pregnancy. Nevertheless, their use in practice is not yet admitted
      because of controversial results in terms of efficacy and safety particularly on the
      conceptus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>implantation rate</measure>
    <time_frame>Time Frame: 5 weeks after IVF/ICSI</time_frame>
    <description>number of gestational sacs per number of embryos transferred</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>positive pregnancy test</measure>
    <time_frame>Time Frame: 2 weeks after IVF/ICSI</time_frame>
    <description>confirmed by beta-hCG 14 days post embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy</measure>
    <time_frame>Time Frame: 12 weeks after IVF/ICSI</time_frame>
    <description>presence of foetal heart beat at 12 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delivery rate</measure>
    <time_frame>Time Frame: 26 weeks after IVF/ICSI</time_frame>
    <description>birth of baby beyond 26 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early pregnancy loss</measure>
    <time_frame>Time Frame: miscarriage before 5 weeks of gestation</time_frame>
    <description>loss of embryo before 5 weeks of gestation, chemical pregnancy and extra-uterine pregnancy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ovarian hyperstimulation syndrome OHSS</measure>
    <time_frame>Time Frame: from date of triggering until 2 weeks after pregnancy test]</time_frame>
    <description>early and late onset Ovarian hyper stimulation syndrome</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">328</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>GnRH agonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Triptorelin 0.1mg Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg.
Other Names:
• Decapeptyl 0.1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin 0.1 mg</intervention_name>
    <description>a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.</description>
    <arm_group_label>GnRH agonist</arm_group_label>
    <other_name>Decapeptyl 0.1 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Female age &lt; 40 years No uterine (fibroids, mullerian malformations), ovarian (
        endometrioma) or adnexa (hydrosalpinx) abnormalities• Baseline FSH and LH &lt; 12
        IU/l.Patients with at least one embryo at transfer time

        Exclusion Criteria:

          -  Very high risk of OHSS (&gt; 30 follicles &gt; 12 mm the day of ovulation triggering). •
             Reduced ovarian reserve

               -  Fertilization failure

               -  Severe endocrinopathy

               -  Azoospermia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdelhamid Benmachiche, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ibn roch infertility centre, cité boussouf, Constantine Algeria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ibnrochd Clinic</name>
      <address>
        <city>Constantine</city>
        <zip>25000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ibnrochd IVF center</name>
      <address>
        <city>Constantine</city>
        <zip>25000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Algeria</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2017</study_first_submitted>
  <study_first_submitted_qc>January 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2017</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Ibn Rochd</investigator_affiliation>
    <investigator_full_name>benmachiche abdelhamid</investigator_full_name>
    <investigator_title>Dr benmachiche abdelhamid, private infertility centre, Ibn rochd, constantine, Algeria</investigator_title>
  </responsible_party>
  <keyword>GnRH agonist trigger</keyword>
  <keyword>IVF</keyword>
  <keyword>Luteal phase support</keyword>
  <keyword>Mid-luteal GnRH agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

